GRANULOMATOSIS WITH POLYANGIITIS
Clinical trials for GRANULOMATOSIS WITH POLYANGIITIS explained in plain language.
Never miss a new study
Get alerted when new GRANULOMATOSIS WITH POLYANGIITIS trials appear
Sign up with your email to follow new studies for GRANULOMATOSIS WITH POLYANGIITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a dengue vaccine be safe for autoimmune patients? new trial seeks answers
⭐️ VACCINE ⭐️ Recruiting nowThis study is testing a live attenuated dengue vaccine (Butantan-DV) in people aged 12–59 with autoimmune rheumatic diseases (like rheumatoid arthritis or lupus) who are stable and on low or no immune-suppressing drugs. Researchers want to see if the vaccine triggers a good immun…
Matched conditions: GRANULOMATOSIS WITH POLYANGIITIS
Phase: PHASE4 • Sponsor: University of Sao Paulo General Hospital • Aim: ⭐️ VACCINE ⭐️
Last updated May 13, 2026 15:58 UTC
-
Could a 4-Week steroid course be safer for vasculitis patients?
Disease control Recruiting nowThis study tests whether a shorter, lower-dose steroid treatment (4 weeks) combined with standard medications can safely control ANCA-associated vasculitis in people with severe kidney involvement. The goal is to reduce serious infections while still managing the disease. About 3…
Matched conditions: GRANULOMATOSIS WITH POLYANGIITIS
Phase: PHASE3 • Sponsor: Ottawa Hospital Research Institute • Aim: Disease control
Last updated May 17, 2026 01:37 UTC
-
New hope for rare autoimmune disease: obinutuzumab targets relapse
Disease control Recruiting nowThis study tests whether the drug obinutuzumab can safely bring the disease under control in people with a relapsing form of PR3-ANCA vasculitis (Wegener's). About 33 adults with active disease will receive the drug and be followed for 6 months. The goal is to stop symptoms, clea…
Matched conditions: GRANULOMATOSIS WITH POLYANGIITIS
Phase: PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated May 17, 2026 01:33 UTC
-
New hope for patients with Treatment-Resistant autoimmune disease
Disease control Recruiting nowThis study aims to find the best treatment for patients with granulomatosis with polyangiitis (GPA), a serious autoimmune disease, when standard therapies have failed. It will compare three different drug strategies involving combinations of medications like rituximab, tocilizuma…
Matched conditions: GRANULOMATOSIS WITH POLYANGIITIS
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Apr 07, 2026 14:38 UTC